Register for free to
view the full innovation profile.
Our detection assay is an immunocomplex based approach with magnetic nanoprobe for sensitive detection of the target biomarker in different body fluids including blood serum.
About
Our detection assay is an immunocomplex based approach with magnetic nanoprobe for sensitive detection of the target biomarker in different body fluids including blood serum, saliva and urine. Once the target biomarker is captured, a sandwich immunocomposite will be formed. The immunocomposite will then be labelled by our tailor-made fluorophore which gives amplified fluorescence signal for quantification. When comparing to commercially available ELISA kits, our new diagnostic kit provides additional options on the sample types and allows testing on saliva and urine. Furthermore, our assay is 100x more sensitive than the commercially available ELISA kit. The limit of detection (LOD) is down to Femto (10E-15) molar regime (0.104 pg/mL), that means the concentration requirement of AD biomarkers being detected for the new kit is much lower than the cut-off for those ELISA kits. Besides, our new kit takes only 1.5 hrs to obtain result while the ELISA kit may generally take 18 hrs for that. For a typical analysis, speed is one of the merits. It saves running cost. Short time allows future point of care products more feasible. Last but not least, the cost of the new kit is about 100 USD, which is 50 times cheaper than the ELISA kit. Key features: - Non-invasive - Ultra-sensitive (100x more sensitive than commercially available ELISA kit) - Cost-effective, simple and direct AD early detection and diagnostics - Low sample consumption (a few µL)
Key Benefits
- Early detection and diagnostic for neurodegenerative diseases, which is cost-effective, simple and quick - Measure the subtle changes in the expression profile of disease-associated biomarkers
Applications
With our novel nanoparticle-based technology, a diagnosis kit is developed for: - High-throughput detection of Alzheimer’s Disease biomarkers - Non-invasive point-of-care diagnosis of Alzheimer’s Disease Besides, two different diagnostic approaches will be further developed: 1) A non-invasive and user-friendly magnetic nanoparticle platform for direct quantification of circulating biomarkers in body fluids. 2) A novel biomarker specific MRI contrast agent for in-vivo imaging of the disease-associated protein plaque in the brain. These diagnostic tools could provide a practical platform for population-wide screening for neurodegenerative diseases.